Observational Registry for Cardiac Ablation in Atrial Fibrillation in Mexico (ORCA-AF)
Solís-Gómez, Juan Carlos; Gómez, Alexis; Pérez, Hipolito Alfredo; Zenteno, Rodrigo; Narváez, Carlos A; García, Gabriela; Vargas, Christian; Álvarez, Abdul; Escamilla, Edgar; Rivera, Salomón; Zempoalteca, Juan Carlos; Soto, Hugo; Leiva, Erika; Sandoval-Diez, Edurne; Robledo-Nolasco, Rogelio
ABSTRACT
Introduction: Atrial Fibrillation (AF) is a prevalent chronic arrhythmia that affects approximately 4% of the Mexican population. AF correlates with an elevated risk of myocardial infarction, increased rate of hospitalizations, and mortality. In recent years, radiofrequency Pulmonary Vein Isolation (PVI) for cardiac ablation has emerged as the frontline intervention for symptomatic AF.
Material and methods: a retrospective observational study was conducted at General Hospital "Tacuba" ISSSTE to evaluate the clinical characteristics and antiarrhythmic management of patients with AF undergoing PVI utilizing the CARTO 3 three-dimensional electromagnetic mapping system with follow-up assessments conducted at 3, 6, and 12 months post-PVI.
Results: the median time for patients to discontinue antiarrhythmic treatment post-PVI was three months. Amiodarone was the most prescribed antiarrhythmic drug. A significant reduction in the percentage of patients on antiarrhythmic treatment was observed post-PVI. The study showed a 95.9% success rate for radiofrequency PVI cardiac ablation procedures.
Conclusion: the study suggests that radiofrequency PVI is an effective and safe treatment for AF in protocolized patients, where ablative therapy has shown the most significant impact on disease control and clinical and likely economic positive effects in reducing the disease burden.
